| Cat.No. | Name | Information |
|---|---|---|
| M58974 | Codrituzumab-MMAE (CHO) | Codrituzumab-MMAE is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). |
| M40765 | Datopotamab deruxtecan | Datopotamab deruxtecan is an antibody-coupled drug (ADC) consisting of a humanized, monoclonal antibody targeting human trophoblast cell surface glycoprotein antigen 2 (Trop2) conjugated to an innovative DNA topoisomerase I inhibitor (DXd) for use in studies related to non-small cell lung cancer (NSCLC). |
| M40546 | Trastuzumab Emtansine | Trastuzumab Emtansine is a HER2-targeting antibody-drug concatenation (ADC) that can be used in studies related to HER2-positive metastatic breast cancer. |
| M40543 | Tisotumab Vedotin | Tisotumab Vedotin is a tissue factor-directed antibody-drug conjugate (ADC) containing a tissue factor-specific fully human monoclonal antibody (TF-011) conjugated to monomethylmethane auristatin E (MMAE), which can be used in studies related to cervical cancer. |
| M25312 | Zilovertamab vedotin | Zilovertamab vedotin (VLS-101) is a novel antibody-drug conjugate comprising the humanized monoclonal antibody zilovertamab and and the anti-microtubule cytotoxin monomethyl vedotin. Zilovertamab vedotin binding to tumor cell ROR1 results in rapid internalization, trafficking to lysosomes, antibody–drug conjugate cleavage, and monomethyl vedotin release. Zilovertamab vedotin induces apoptosis. Zilovertamab vedotin can be used in research of cancer. |
| M25118 | Farletuzumab MMAE | Farletuzumab MMAE is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab conjugated to MMAE. |
| M24699 | Vandortuzumab vedotin | Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer. |
| M24619 | Enfortumab vedotin-ejfv | Enfortumab vedotin-ejfv is an anti-Nectin-4 antibody-drug conjugate (ADC) for the management of urothelial carcinoma. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE via a protease-cleavable maleimidocaproylvaline-citrulline linker. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
